New Immune-Boosting drug combo targets Hard-to-Treat cancers

NCT ID NCT07594106

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and how well the treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma clear cell renal carcinoma metastatic prostate carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA (CCRCC) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope Chicago, City of Hope Cancer Center Chicago
RECRUITING

Zion, Illinois, 60099, United States
City of Hope Phoenix
RECRUITING

Goodyear, Arizona, 85338, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.